Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Q2 2025 Earnings Call Transcript August 13, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $ ...

Q1 2026 Earnings Call Transcript August 13, 2025 Aethlon Medical, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.68. Operator: Good afternoon, and welcome to ...